Alzheimer's Disease Long-term Follow-up Study (ALF Study)

• Status: Completed
• Trial end date: 2006-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Open study for efficacy and safety of donepezil treatment during 48 weeks

• Phase: Phase 4

Details

• Lead Sponsor: Eisai Korea Inc.
• Treatments: Donepezil

Criteria

Inclusion criteria

• Men or women aged 40 to 90

• Diagnosis of dementia according to DSM-IV

• Diagnosis of probable AD as defined by NINCDS-ADRDA criteria

• Mild to moderate AD at baseline, as defined by MMSE score of 10 to 26

• Patients were generally healthy and ambulatory or ambulatory aided

• Patients did not take acetylcholinesterase inhibitor 4 weeks before screening

• Patients have useful MRI results 3 months before screening

Exclusion

• If they have evidence of TIA or major infarction

• Epilepsy patients

• If they have evidence of other degenerative or psychiatric disorder, other serious disorder, alcoholism or drug abuse

• If they sensitive to acetylcholinesterase

• If they taken concomitant medication which were not allowed